JGC
COLL icon

J. Goldman & Co’s Collegium Pharmaceutical COLL Stock Holding History

J. Goldman & Co’s Portfolio COLL Stock Details COLL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-50,000
Closed -$737K – 252
2018
Q3 		$737K Buy
+50,000
New +$886K 0.05% 203

Other funds holding COLL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

J. Goldman & Co's COLL Position: Q3 2025 in Review

J. Goldman & Co sold out of Collegium Pharmaceutical (COLL) in Q3 2025, closing a stake of 243,448 shares — an estimated $7.2M sold.

J. Goldman & Co first reported a position in COLL in Q2 2016 and held it in 21 quarters. The position peaked at $23.3M in Q3 2018. 244 funds tracked by Wall St. Rank hold COLL as of Q3 2025.

  • J. Goldman & Co reported no remaining Collegium Pharmaceutical position as of Q3 2025 after selling out during the quarter.
  • J. Goldman & Co sold 243,448 Collegium Pharmaceutical shares in Q3 2025, an estimated $7.2M.
  • J. Goldman & Co first reported a position in Collegium Pharmaceutical in Q2 2016 and held it in 21 quarters.
  • J. Goldman & Co's Collegium Pharmaceutical position peaked at $23.3M in Q3 2018.
  • 244 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q3 2025.

Based on J. Goldman & Co's 13F filing for Q3 2025, filed 14 Nov 2025.